DOCSLIB.ORG

CME Lunch Sympo Slides V2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CME Lunch Sympo Slides V2 An Independent CME Lunch Program A Closer Look at S1P Immunomodulator Therapeutics to Improve Outcomes in Patients With Relapsing Multiple Sclerosis Wednesday, February 22, 2017 12:30-1:30 PM Orlando, Florida Provided by AcademicCME This activity has been supported by an independent educational grant from Actelion Pharmaceuticals Inc Sponsorship & Support §This activity is supported by an independent educational grant from Actelion Pharmaceuticals Inc §This activity is provided by AcademicCME Accreditation & Credit Designation Accreditation Statement AcademicCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement AcademicCME designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Instructions for Receiving CME Credit In order to claim CME credit, please complete the evaluation form at the end of the symposium using the provided iPad. CME Lunch Symposium Evaluation Form Wednesday, February 22, 2017 You must complete this evaluation form to receive acknowledgement for completing this activity. First Name: ___________ __ __ __ __ __ __ __ Last Name: ___________ __ __ __ __ __ __ _ Degree: __________ Faculty Introductions Chair Fred D. Lublin, MD Saunders Family Professor of Neurology Director, Corinne Goldsmith Dickinson Center for MS Icahn School of Medicine at Mount Sinai New York, New York Faculty Timothy L. Vollmer, MD Mark S. Freedman, MD Professor Department of Neurology Professor of Medicine University of Colorado Health Sciences Center University of Ottawa Co-Director of the RMMSC at Anschutz Senior Scientist Medical Center and Medical Director-Rocky Ottawa Hospital Research Institute Mountain MS Center Ottawa, Ontario, Canada Aurora, Colorado Faculty Disclosures Fred D. Lublin, MD Consultant/Advisor: AbbVie Inc.; Actelion Pharmaceuticals; Acorda Therapeutics; Akros Pharma Inc.; Amgen Inc.; Atara Biotherapeutics; Bayer AG; Biogen; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Mapi-Pharma Ltd.; Medday; MedImmune; POLYPHARMA; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; Roche; Teva Pharmaceutical Industries Ltd.; TG Therapeutics, Inc.; Toyama Grant/Research Support: Biogen; Celgene Corporation; Genzyme Corporation; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; Teva Pharmaceutical Industries Ltd.; Transparency Life Sciences Speaker's Bureau: Genentech, Inc.; Genzyme Corporation Mark S. Freedman, MD Consultant/Advisor:Actelion Pharmaceuticals; Bayer AG; Biogen; Chugai Pharmaceutical Co., Ltd.; EMD Serono, Inc.; Genzyme Corporation; MedDay; Merck & Co.; Novartis Pharmaceuticals Corporation; Roche; sanofi-aventis U.S. LLC; Teva Canada Innovation Grant/Research Support:Genzyme Corporation Speaker's Bureau: Genzyme Corporation Timothy L. Vollmer, MD Consultant/Advisor: AbbVie Inc.; Alcimed; American Academy of Neurology; CB Partners; Capmaels and Rasford; Celestial IntasPharmaceuticals LTD; Compass Learning; Genetech/Roche; Genzyme/Sanofi; Goodwin Procter, LLP; Guthy Jackson Charitable Foundation; IMS Consulting Group; MedScape; Novartis Pharmaceuticals Corporation; Oxford Pharmagenesis; Patient Centered Outcomes Research Institute; Sommer Consulting; Teva Neuroscience; Xenoport, Inc. Grant/Research Support: Genzyme Corporation; Teva Pharmaceutical Industries Ltd.; NIH/NINDS; Rocky Mountain MS Center; EMD Sereno, Inc.; Biogen Idec; Ono Pharmaceuticals; Acorda Pharmaceuticals; MedImmune Educational Objectives 1. Discuss the recent scientific advancements of emerging S1P immunomodulators. 2. Analyze the current clinical trial data concerning S1P efficacy and safety including, head to head superiority data and add-on therapy data. 3. Apply the most current evidence based medicine to develop individualized treatment plans for patients with relapsing multiple sclerosis. Agenda I. Welcome and introductions Fred D. Lublin, MD II. Recent Scientific Advancements of S1P Immunomodulators Mark S. Freedman, MD III. Clinical Trial Data Analysis: Interpreting S1P Evidence Based Medicine for Relapsing MS Mark S. Freedman, MD IV. New MS Research Strategies and Approaches Timothy L. Vollmer, MD V. Panel Discussion and Conclusion Fred D. Lublin, MD Clinical Trial Development Progam for S1P Receptor Modulators in RMS Mark S. Freedman MSc MD FANA FAAN FRCPC Professor of Medicine (Neurology) University of Ottawa Sr. Scientist The Ottawa Hospital Research Institute S1P Receptors – A Pleiotropic System S1P is a phospholipid released by platelets, mast and other cells S1P stimulates 5 G-protein coupled receptors located on endothelial cells, cardiac myocytes S1P receptors are expressed in a wide variety of tissues The different S1P1 S1P2 S1P3 S1P4 S1P5 receptors induce a variety of Cellular responses: biological proliferation, angiogenesis, migration, cytoskeleton organization, endothelial cell chemotaxis, responses immune cell trafficking, mitogenesis Lymphocyte Migration: Unique Role of S1P1 Receptor Modulator This image cannot currently be displayed. Naïve T cell Antigen-presenting cell Activated T cell Effector T cell Lymph node Target organ S1P1 Receptor Modulators: Effects on the Immune System Significantly affects: Does not affect: ¡ Th17 cells ¡ Monocytes, NK-cells, and neutrophils ¡ Central memory T cells ¡ Effector memory T cells ¡ B cells involved in Sequestration in immunosurveillance lymphoid organs ¡ Killing of cells resulting in a dose- Preservation of mechanism dependent decrease in of innate immune system total lymphocyte counts Comparison of Main S1P Receptor Modulators in MS Study Agent Fingolimod Ponesimod Siponimod Ozanimod Ceralifimod# t½ (hrs/days) 6-9 days 30 hrs 30 hrs 19 hrs 85 hrs Lymphocyte 1-2 months 3-6 days 7 days 3 days 14 days Recovery S1P Receptors 1, 3, 4, 5 1 (3, 5) 1, 5 1, 5 1, 5 Pro-drug (needs to be Yes No No No No phosphorylated) Study Phase II & III II II & III* II & III II Significant effects on MRI activity Yes Yes Yes Yes Yes Significant Reduction of ARR Yes No Yes No NA *in SPMS only #not being actively pursued for further development Comparison of Main S1P Receptor Modulators in MS Study Agent Fingolimod Ponesimod Ozanimod Siponimod Drug Placebo Drug Placebo Drug Placebo Drug Placebo Trial Duration 24 6 6 6 (months) Patients (n) 425 418 119 121 83 88 50 45 Mean Gd+ Lesions 0.2 1.1 1.4 6.2 0.2 3.2 0.28 2.9 Pts free of Gd+ lesions (6 mths) 90% 62% na na 88% 59% na na Mean # new/enlarging 2.5 9.8 0.5 0.7 na na 0.2# 2.09 lesions (6 mth) ARR 0.18 0.4 0.42* 0.52 0.24+ 0.5 0.28 0.58 Bradycardia 2.1% 0.7% 2% 0 0 1% 28% 2% #2 mg dose; *20 mg dose; +1 mg dose Ponesimod: Clinical Trial Development in MS PK/PD: Rapidly absorbed, tmax 2.5 – 4 hours, t½ = 32 hours No relevant effect of food No relevant interaction with oral contraceptives Predominantly excreted in feces Comprehensive evaluation of safety and tolerability ¡>1000 subjects exposed, some treated for >6 years ¡15 Phase I, 3 Phase II studies (MS + other conditions) ¡Titration scheme for mitigation of 1st dose effect on heart rate Demonstrated efficacy in MS and psoriasis Ponesimod: Safety Issues First dose effects (bradycardiaand AV conduction delays) Pulmonary function effects (reduced FEV1), rapidly reversible Transient liver enzyme elevations with no bilirubin elevation Few cases of macular edema (<1% incidence), resolved after discontinuation Lymphocyte count reduction, rapidly reversible Phase II Dose Finding Study in MS Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study in patients with relapsing-remitting multiple sclerosis (RRMS), 464 patients randomized Randomization Placebo (n=121) 10 mg o.d. ponesimod (n=108) 20 mg o.d. ponesimod (n=116) Baseline 40 mg o.d. ponesimod (n=119) Screening Treatment FollowFollow--upup 24 weeks Core Extension Efficacy endpoints: • Primary – cumulative number of new Gd+ T1-lesions per patient at weeks 12, 16, 20 and 24. • Secondary - ARR during 24 weeks of treatment Olsson T, et al. J Neurol Neurosurg Psychiatry. 2014;85:1198–1208. Primary Endpoint: Cumulative Number of New T1 Gd+ Lesions From Week 12 to Week 24 Per-protocol population SE) ± + lesions 43% reduction Gd 1 * 77% reduction 83% reduction *** Cumulative new T new Cumulative *** from week 12 to (Meanto weekweekfrom2412 *p<0.05, ***p<0.0001 vs placebo Olsson T, et al. J Neurol Neurosurg Psychiatry. 2014;85:1198–1208. Secondary Endpoint: Annualized Relapse Rate up to Week 24 All-treated population 0.9 0.8 52% 0.7 0.6 0.5 p = 0.0363 0.4 0.3 0.2 Annualized relapse rate (+ 95%CI) 0.1 0.525 0.332 0.417 0.251 0 Placebo Ponesimod 10 mg Ponesimod 20 mg Ponesimod 40 mg • Annualized confirmed relapse rate estimated from negative binomial regression model • Studies continuing with 20 mg dose due to toxicity of 40 mg Olsson T, et al. J Neurol Neurosurg Psychiatry. 2014;85:1198–1208. Ponesimod: Effect on Lymphocytes All-treated set 10 0 -10 Ponesimod 40 mg -20 Ponesimod 20 mg -30 Ponesimod 10 mg Placebo -40 -50 -60 lymphocyte (%)count -70 Meanchangefromin baseline -80 Number of patients at each visit 113 110 111 99 88 92 88 87 110 107 107 101 99 96 96 96 101 96 100 95 97 91 90 90 110 113 112 110 103 105 105 105 Olsson T, et al. J Neurol Neurosurg Psychiatry. 2014;85:1198–1208. Ponesimod: Adverse Events (Observed in ≥5% of Patients) All-treated population Placebo Ponesimod 10 mg Ponesimod 20 mg
Load more

Recommended publications
  • Therapeutic Use of a Selective S1P1 Receptor Modulator Ponesimod in Autoimmune Diabetes
    Therapeutic Use of a Selective S1P1 Receptor Modulator Ponesimod in Autoimmune Diabetes Sylvaine You1,2, Luca Piali3, Chantal Kuhn1,2, Beat Steiner3, Virginia Sauvaget1,2, Fabrice Valette1,2, Martine Clozel3, Jean-Franc¸ois Bach1,2, Lucienne Chatenoud1,2* 1 Universite´ Paris Descartes, Sorbonne Paris Cite´, Paris, France, 2 Institut National de la Sante´ et de la Recherche Me´dicale, Unite´ 1013, Paris, France, 3 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland Abstract In the present study, we investigated the therapeutic potential of a selective S1P1 receptor modulator, ponesimod, to protect and reverse autoimmune diabetes in non-obese diabetic (NOD) mice. Ponesimod was administered orally to NOD mice starting at 6, 10, 13 and 16 weeks of age up to 35 weeks of age or to NOD mice showing recent onset diabetes. Peripheral blood and spleen B and T cell counts were significantly reduced after ponesimod administration. In pancreatic lymph nodes, B lymphocytes were increased and expressed a transitional 1-like phenotype. Chronic oral ponesimod treatment efficiently prevented autoimmune diabetes in 6, 10 and 16 week-old pre-diabetic NOD mice. Treatment withdrawal led to synchronized disease relapse. Ponesimod did not inhibit the differentiation of autoreactive T cells as assessed by adoptive transfer of lymphocytes from treated disease-free NOD mice. In addition, it did not affect the migration, proliferation and activation of transgenic BDC2.5 cells into the target tissue. However, ponesimod inhibited spreading of the T cell responses to islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). Treatment of diabetic NOD mice with ponesimod induced disease remission. However, here again, upon treatment cessation, the disease rapidly recurred.
    [Show full text]
  • Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: a Review Article
    biomedicines Review Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article Stanley Cohan, Elisabeth Lucassen, Kyle Smoot, Justine Brink and Chiayi Chen * Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Providence St, Vincent Medical Center, Portland, OR 97225, USA; [email protected] (S.C.); [email protected] (E.L.); [email protected] (K.S.); [email protected] (J.B.) * Correspondence: [email protected]; Tel.: +1-503-216-1012 Received: 27 May 2020; Accepted: 15 July 2020; Published: 18 July 2020 Abstract: Sphingosine-1-phosphate (S1P), via its G-protein-coupled receptors, is a signaling molecule with important regulatory properties on numerous, widely varied cell types. Five S1P receptors (S1PR1-5) have been identified, each with effects determined by their unique G-protein-driven downstream pathways. The discovery that lymphocyte egress from peripheral lymphoid organs is promoted by S1P via S1PR-1 stimulation led to the development of pharmacological agents which are S1PR antagonists. These agents promote lymphocyte sequestration and reduce lymphocyte-driven inflammatory damage of the central nervous system (CNS) in animal models, encouraging their examination of efficacy in the treatment of multiple sclerosis (MS). Preclinical research has also demonstrated direct protective effects of S1PR antagonists within the CNS, by modulation of S1PRs, particularly S1PR-1 and S1PR-5, and possibly S1PR-2, independent of effects upon lymphocytes. Three of these agents, fingolimod, siponimod and ozanimod have been approved, and ponesimod has been submitted for regulatory approval. In patients with MS, these agents reduce relapse risk, sustained disability progression, magnetic resonance imaging markers of disease activity, and whole brain and/or cortical and deep gray matter atrophy.
    [Show full text]
  • Oral MS Disease-Modifying Therapies C21142-A
    Drug and Biologic Coverage Criteria Effective Date: 05/01/2019 Last P&T Approval/Version: 07/28/2021 Next Review Due By: 08/2022 Policy Number: C21142-A Oral MS Disease-Modifying Therapies PRODUCTS AFFECTED Mayzent (siponimod), Aubagio (teriflunomide), Gilenya (fingolimod), Mavenclad (cladribine), Tecfidera (dimethyl fumarate), Vumerity (diroximel fumarate), Bafiertam (monomethyl fumarate),dimethyl fumarate, Zeposia (ozanimod), Ponvory (ponesimod) COVERAGE POLICY Coverage for services, procedures, medical devices, and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines Documentation Requirements: Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive DIAGNOSIS: Multiple Sclerosis REQUIRED MEDICAL INFORMATION: A.
    [Show full text]
  • Risk Assessment and Risk Mitigation Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213498Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Division of Risk Management (DRISK) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Application Type NOA Application Number 213498 POU FA Goal Date March 18, 2021 OSE RCM # 2020-534 Reviewer Name(s) Carlisha Gentles, PharmD, BCPS Team Leader Jacqueline Sheppard, PharmD Deputy Director Doris Auth, PharmD Review Completion Date March 2, 2021 Subject Eva luation of Need for a REMS Established Name Ponesimod Trade Name Ponvory Name of Applicant Janssen Pharmaceuticals Inc Therapeutic Class Sphingosine 1-phosphate (SlP) receptor modulator Formulation(s) Film-coated tablets: 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 20 mg Dosing Regimen Treatment init iation with a 14-day titration (see table), followed by a maintenance regimen of 20 mg orally once daily Treatment init iation titration: Titration Day Daily Dose Day 1 a nd 2 2mg Day 3 a nd 4 3mg Day 5 a nd 6 4mg Day7 Smg Dav8 6mg Day9 7mg Day10 8mg Day ll 9mg Day 12, 13, and 14 10mg 1 Reference ID 4755518 Table of Contents EXECUTIVE SUMMARY ......................................................................................................................................................... 3 1 Introduction ....................................................................................................................................................................
    [Show full text]
  • Multiple Sclerosis
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-2596 Drug Class Update with New Drug Evaluations: Multiple Sclerosis Date of Review: June 2021 Date of Last Review: August 2020 Dates of Literature Search: 02/03/2020 – 03/01/2021 Generic Name: Ofatumumab Ponesimod Brand Name (Manufacturer): Kesimpta (Novartis) Ponvory (Janssen) Dossier Received: yes, for ofatumumab Current Status of PDL Class: See Appendix 1. Purpose for Class Update: Evidence for the comparative effectiveness of disease modifying drugs (DMDs) for multiple sclerosis (MS) was last reviewed by the Oregon Pharmacy & Therapeutic Committee (P&T) in August 2020 as summarized in a Drug Effectiveness Review Project (DERP) report. This review examines new comparative evidence of DMDs for MS published since 2020 and summarizes the evidence for 2 new DMDs, ofatumumab and ponesimod, approved to treat relapsing forms of MS. Research Questions: 1. What is the comparative effectiveness and efficacy of DMDs for MS? 2. Do DMDs for MS differ in harms? 3. Are there subgroups of patients with MS based on demographics (age, racial or ethnic groups, and gender), socioeconomic status, concomitant medications, severity of disease, or co-morbidities for which one DMD is more effective or associated with fewer adverse events? 4. What is the evidence for efficacy and safety for use of ofatumumab in relapsing MS? 5. What is the evidence for efficacy and safety of ponesimod in relapsing MS ? Author: Deanna Moretz, PharmD, BCPS Conclusions: Multiple Sclerosis Disease-Modifying Drugs No new evidence of comparative efficacy or effectiveness of DMDs approved to treat MS has been published since the last MS class review.
    [Show full text]
  • Ponesimod (Ponvory) Reference Number: ERX.SPA.437 Effective Date: 06.01.21 Last Review Date: 05.21 Line of Business: Commercial, Medicaid Revision Log
    Clinical Policy: Ponesimod (Ponvory) Reference Number: ERX.SPA.437 Effective Date: 06.01.21 Last Review Date: 05.21 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Ponesimod (Ponvory™) is a sphingosine 1-phosphate receptor modulator. FDA Approved Indication(s) Ponvory is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary. It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Ponvory is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Multiple Sclerosis (must meet all): 1. Diagnosis of one of the following (a, b, or c): a. Clinically isolated syndrome, and member is contraindicated to all, or has experienced clinically significant adverse effects to two, of the following: Aubagio®, glatiramer (Copaxone®, Glatopa®), an interferon-beta agent (Betaseron® or Rebif®); b. Relapsing-remitting MS, and failure of two of the following, unless clinically significant adverse effects are experienced or all are contraindicated: Aubagio®, dimethyl fumarate, Gilenya®, glatiramer (Copaxone®, Glatopa®), an interferon-beta agent (Betaseron® or Rebif®), Kesimpta®, Mayzent®, Ocrevus®, Tysabri®, Vumerity®, Zeposia®;* *Prior authorization is required for all disease modifying therapies for MS.
    [Show full text]
  • Rxoutlook® 4Th Quarter 2020
    ® RxOutlook 4th Quarter 2020 optum.com/optumrx a RxOutlook 4th Quarter 2020 While COVID-19 vaccines draw most attention, multiple “firsts” are expected from the pipeline in 1Q:2021 Great attention is being given to pipeline drugs that are being rapidly developed for the treatment or prevention of SARS- CoV-19 (COVID-19) infection, particularly two vaccines that are likely to receive emergency use authorization (EUA) from the Food and Drug Administration (FDA) in the near future. Earlier this year, FDA issued a Guidance for Industry that indicated the FDA expected any vaccine for COVID-19 to have at least 50% efficacy in preventing COVID-19. In November, two manufacturers, Pfizer and Moderna, released top-line results from interim analyses of their investigational COVID-19 vaccines. Pfizer stated their vaccine, BNT162b2 had demonstrated > 90% efficacy. Several days later, Moderna stated their vaccine, mRNA-1273, had demonstrated 94% efficacy. Many unknowns still exist, such as the durability of response, vaccine performance in vulnerable sub-populations, safety, and tolerability in the short and long term. Considering the first U.S. case of COVID-19 was detected less than 12 months ago, the fact that two vaccines have far exceeded the FDA’s guidance and are poised to earn EUA clearance, is remarkable. If the final data indicates a positive risk vs. benefit profile and supports final FDA clearance, there may be lessons from this accelerated development timeline that could be applied to the larger drug development pipeline in the future. Meanwhile, drug development in other areas continues. In this edition of RxOutlook, we highlight 12 key pipeline drugs with potential to launch by the end of the first quarter of 2021.
    [Show full text]
  • Benefit–Risk Profile of Sphingosine-1-Phosphate
    Drugs (2017) 77:1755–1768 DOI 10.1007/s40265-017-0814-1 REVIEW ARTICLE Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis 1 2,3 4 5 Giancarlo Comi • Hans-Peter Hartung • Rajesh Bakshi • Ian M. Williams • Heinz Wiendl6 Published online: 13 September 2017 Ó The Author(s) 2017. This article is an open access publication Abstract Since the approval of fingolimod, several selec- studies demonstrated sustained efficacy and raised no new tive sphingosine-1-phosphate receptor modulators have safety concerns, with no increases in macular edema, entered clinical development for multiple sclerosis. How- infection, or malignancy rates. Switch studies identified no ever, side effects can occur with sphingosine-1-phosphate safety concerns and greater patient satisfaction and per- receptor modulators. By considering short-term data across sistence with fingolimod when switching from the drug class and longer term fingolimod data, we aim to injectable therapies with no washout period. Better out- highlight the potential of sphingosine-1-phosphate receptor comes were seen with short than with long washouts when modulators in multiple sclerosis, while offering reassur- switching from natalizumab. The specific immunomodu- ance that their benefit–risk profiles are suitable for long- latory effects of sphingosine-1-phosphate receptor modu- term therapy. Short-term fingolimod studies demonstrated lators are consistent with the low observed rates of long- the efficacy of this drug class, showed that cardiac events term, drug-related adverse effects with fingolimod. Short- upon first-dose administration are transient and manage- term data for selective sphingosine-1-phosphate receptor able, and showed that serious adverse events are rare.
    [Show full text]
  • Biologics for Autoimmune Conditions
    © Copyright 2021 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-2596 Drug Class Update: Targeted Immune Modulators for Autoimmune Diseases Date of Review: October 2021 Date of Last Review: October 2020 Dates of Literature Search: 01/01/2020 – 06/09/2021 Current Status of PDL Class: See Appendix 1. Purpose for Class Update: Review new comparative evidence between targeted immune modulators (TIMs) approved by the Food and Drug Administration (FDA) to manage autoimmune conditions. Research Questions: 1. Is there new comparative evidence that TIMs differ in efficacy or effectiveness for alleviating symptoms and stabilizing disease in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), plaque psoriasis (PsO), Crohn’s disease (CD), or ulcerative colitis (UC)? 2. Is there new comparative evidence that TIMs differ in harms when used to treat patients with autoimmune conditions? 3. Are there specific subpopulations for which one TIM is better tolerated or more effective than other available TIMs when used for autoimmune conditions? Conclusions: Since the last class update, 6 high-quality systematic reviews and 5 high-quality guidelines were published. Systematic Reviews In April 2020 the American Gastroenterological Association (AGA) sponsored a systematic review focused on the efficacy and safety of disease-modifying anti-rheumatic drugs (DMARDs) approved
    [Show full text]
  • Ponesimod MBMA ARR Abstract for ECF 2020 Confidential Title
    Ponesimod_MBMA_ARR Abstract for ECF 2020 Confidential Title: Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Model-Based Meta-Analysis for Annualized Relapse Rate Short title: Comparative Efficacy of Relapsing MS Therapies Authors: 1M. Zierhut, 2H. Kracker, 2T. Scherz, 3A. Keenan, 2B. Hennessy Affiliations: 1Janssen Research & Development, San Diego, CA, United States of America, 2Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies, Allschwil, Switzerland, 3Janssen Research & Development, LLC, Spring House, United States of America Corresponding Author: Alexander Keenan Global Market Access Leader, Schizophrenia and Neurodegeneration Janssen Research & Development, LLC Spring House, Pennsylvania E-mail: [email protected] Funding: This work was sponsored by Janssen Research & Development, LLC. Previous submission: A/ECTRIMS 2020, September 9-12, 2020, Washington DC Ponesimod_MBMA_ARR Abstract for ECF 2020 Confidential Abstract (300/300 words) Background: Multiple sclerosis (MS), an inflammatory autoimmune disorder, is responsible for progressive neurological disability among adults. Ponesimod is a selective sphingosine-1- phosphate (S1P) receptor 1 immunomodulator under development for relapsing multiple sclerosis (RMS). Objectives: To assess effects of ponesimod on the annualized relapse rate (ARR) relative to other disease-modifying therapies (DMTs) used for treatment of RMS. Methods: A literature review was performed, returning 154 clinical trials with 58 MS treatments. Only randomized controlled trials (RCTs) with >30 patients receiving monotherapy for RMS for ≥48 weeks were included. Mean ARR for each treatment was modeled and rate ratios (RRs) between treatments were assumed constant from 48-156 weeks. Multiple variables were explored relative treatment effect modifiers: percent of patients with remitting RMS, trial start year, mean disease duration, percent of patients with history of DMT use in<2 years (pDMT), mean relapses, mean age, and mean baseline EDSS score.
    [Show full text]
  • Ponvory (Ponesimod) Annual Review Date: 05/20/2021
    Policy: Ponvory (ponesimod) Annual Review Date: 05/20/2021 Last Revised Date: 05/20/2021 OVERVIEW Ponvory, a sphingosine 1-phosphate receptor modulator, is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease in adults. POLICY STATEMENT This policy involves the use of Ponvory. Prior authorization is recommended for pharmacy benefit coverage of Ponvory. Approval is recommended for those who meet the conditions of coverage in the Criteria and Initial/Extended Approval for the diagnosis provided. Conditions Not Recommended for Approval are listed following the recommended authorization criteria. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis. Because of the specialized skills required for evaluation and diagnosis of patients treated with Ponvory as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Ponvory be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy unless otherwise noted below. RECOMMENDED AUTHORIZATION CRITERIA Coverage of Ponvory is recommended in those who meet the following criteria: 1. Multiple Sclerosis Criteria. Patient must meet the following criteria A) Patient has a relapsing form of multiple sclerosis; AND Note: Examples of relapsing forms of multiple sclerosis include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease.
    [Show full text]
  • Top-Line Summary of Selected Additional Data on Approved Oral Dmts for MS
    PRACTICE AID Top-Line Summary of Selected Additional Data on Approved Oral DMTs for MS This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients. Agent Trial/Results • Results for the European cohort of the phase 4 Teri-PRO study showed Teriflunomide high levels of patient-reported treatment satisfaction with teriflunomide; these results are consistent with the overall Teri-PRO study population1 • A subgroup analysis of the PROTEC study showed DMF therapy was associated with lower 12-month ARRs and fatigue score, consistent with findings in the overall study population2 Dimethyl Fumarate • Interim results from the ESTEEM study showed DMF treatment in newly diagnosed, early MS, and interferon/glatiramer acetate switch patients was associated with significantly lower ARRs after 12 months3 • Among patients with RRMS enrolled in the active-comparator study TRANSFORMS and followed for up to 8 years, 35%-52% experienced confirmed improvements in their disability while on fingolimod4 • Data from the PREFERMS study showed that improvements in BVL, cGMVL, and cognition in the injectable DMT group at end of study Fingolimod were associated with a high proportion of switches to fingolimod5 • Results of the TRANSITION study showed fingolimod was effective in controlling clinical disease activity in patients switched from natalizumab; a treatment gap of ≤8 weeks resulted in the lowest risk of relapse; no new safety signals emerged, and AEs decreased with increasing treatment duration6 ARRs: annualized relapse rates; BVL: brain volume loss; cGMVL: cortical gray matter volume loss; DMF: dimethyl fumarate; RRMS: relapsing-remitting multiple sclerosis.
    [Show full text]